BiotechTube
Home/Race Oncology/Philip Lynch
PL

Philip Lynch

Executive Director & Chief Executive Officer

Race Oncology

Therapeutic Areas

OncologyHematology

Race Oncology Pipeline

DrugIndicationPhase
Bisantrene (RC220)Relapsed/Refractory Acute Myeloid Leukemia (AML)Phase 2

Leadership Team at Race Oncology

DD
Dr. Daniel Tillett
Chief Scientific Officer
DD
Dr. David Fuller
Non-Executive Chairman
DJ
Dr. James Garner
Chief Medical Officer
DP
Dr. Peter Molloy
Non-Executive Director
DG
Dr. Gabriel Kremmidiotis
Former Chief Executive Officer
DF
Dr. Fares Al-Ejeh
Head of Translational Research
View full Race Oncology profile